Call for Abstract

10th International Conference on Neuropharmacology and Neuropharmaceuticals, will be organized around the theme “Recent Innovations in Neuropharmacological Studies”

Neuropharma 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Neuropharma 2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Structure/Function
  • Track 1-2Physiology and signaling
  • Track 1-3Physiological disorders
  • Track 1-4Neurodegenerative diseases
  • Track 1-5Novel therapeutic approaches and potential applications
  • Track 2-1Neurogenesis and repair
  • Track 2-2Studies on neuronal circuits
  • Track 2-3GABA , 5HT receptors and its neuronal development
  • Track 2-4Synopathy in neurodegenerative diseases and ageing
  • Track 2-5Manipulation of ion channels by drugs
  • Track 3-1Clinical neuropharmacology of drug abuse
  • Track 3-2Clinical neuropharmacology and therapeutics
  • Track 3-3Clinical neuropharmacology of pain
  • Track 4-1Preclinical psychopharmacology
  • Track 4-2Clinical and translational psychopharmacology
  • Track 4-3Psychopharmacology drugs and their interaction with neurotransmitters
  • Track 4-4Dose response relation in psychiatric medications
  • Track 4-5Effect of androgenic anabolic steroids on psychosis
  • Track 4-6Schizophrenia and its dependence on brain chemistry and structure
  • Track 4-7Psychology of psychopharmacology
  • Track 4-8Molecular and synaptic mechanisms
  • Track 5-1Dopamine
  • Track 5-2Neuropeptides
  • Track 5-3Monoamines
  • Track 5-4Human synapses
  • Track 5-5Autism and intellectual disability
  • Track 5-6Advances in astrocyte-neuron interactions in health and disease
  • Track 5-7Interneurons: coordinators of neuronal synchrony
  • Track 5-8Drug interaction in various stages in neurotransmitters
  • Track 5-9Target drugs in summation and co-transmission
  • Track 5-10Serotonin
  • Track 6-1Anxiety and Autism
  • Track 6-2Measuring neural activity in drug abuse
  • Track 6-3Alcoholism- tolerance to and physical dependence
  • Track 6-4Post-traumatic stress disorder and borderline personality disorder
  • Track 6-5Clinical depression and enhanced treatments
  • Track 7-1Mechanism
  • Track 7-2Optical techniques and advances
  • Track 7-3Trans cranial magnetic stimulation
  • Track 7-4Novel trans-synaptic tracing approaches
  • Track 7-5Modern neurocircuitry analysis
  • Track 7-6Neurotechnology
  • Track 7-7Neurotransmitter imbalance
  • Track 7-8Elimination of neurotransmitters
  • Track 7-9Precursors
  • Track 7-10Agonists and antagonists drug effects
  • Track 7-11Brain neurotransmitter system
  • Track 7-12Excitatory and inhibitory actions
  • Track 7-13Neuromodulation and implant
  • Track 8-1Cortical systems and their complexity
  • Track 8-2Transverse myelitis spectrum disorders and prognosis
  • Track 8-3Epilepsy and epileptic seizures
  • Track 8-4Brain Injury and Stroke
  • Track 8-5Huntington’s disease and linkage with cognitive & psychiatric disorders
  • Track 8-6Epigenetics and its role in neuroimmunopharmacology
  • Track 8-7Immuno-pathogenesis of brain tumor
  • Track 8-8Blood Brain Barrier and associated disorders
  • Track 8-9Clinical neuropharmacology of hypothalamic releasing factors
  • Track 9-1Insulin receptor and hypothalamic programming
  • Track 9-2Environmental effects associated with disease
  • Track 9-3Animal cognition and behaviour- Fear and aversive learning and memory
  • Track 9-4Neurocognitive effects associated with therapeutic drugs
  • Track 9-5Symptoms, causes and diagnostics
  • Track 9-6Drug designing and therapeutics
  • Track 9-7Alzheimer’s disease and dementia
  • Track 9-8Pituitary structure and hormone secretion- New Insights
  • Track 9-9Stress, coping and interactions
  • Track 9-10Role of amyloid protein in Alzheimer
  • Track 10-1Impact of genetic mutations
  • Track 10-2Interdependent disorders such as neurodegenerative disorders and ageing
  • Track 10-3Anxiety, depression and stress level in Parkinson’s
  • Track 10-4Approaches involved in diagnostics
  • Track 10-5Drug designing and therapeutics
  • Track 11-1Neurological disorders and implications for society
  • Track 11-2Brain interventions and brain imaging
  • Track 11-3Neuroethics of neurological treatments and management
  • Track 11-4Neuroethics associated with different stages of consciousness and related disorders
  • Track 12-1Neuroprotection
  • Track 12-2Neurovirology
  • Track 12-3Neuro-radiology
  • Track 12-4Neurotoxicity
  • Track 12-5Neurogenetics
  • Track 12-6Neuro-Ophthalmology
  • Track 12-7Neuroscience
  • Track 12-8Novel drugs and their mechanisms
  • Track 12-9Gene therapy in neurological disorders
  • Track 12-10Neural engineering
  • Track 13-1Interactions with organic compounds
  • Track 13-2Alcohol and neurotransmitter interactions
  • Track 13-3Interactions between Neurochemical and Environmental Influences
  • Track 14-1Novel therapeutic approaches in epilepsy
  • Track 14-2Advances in pharmacological therapy of Parkinson’s disease
  • Track 14-3Neuropharmacology of emesis
  • Track 14-4Current therapeutic strategy in Alzheimer’s disease
  • Track 14-5Advances in neuropharmacological rehabilitation for brain dysfunction